Back to Clinical Trials
Phase 1Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Sponsored by Frontier Medicines Corporation

About this study

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Where this study is enrolling (12)

  • University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center

    La Jolla, California

    I'm interested

  • University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

    I'm interested

  • Northwest Cancer Centers

    Dyer, Indiana

    I'm interested

  • The University of Kansas Cancer Center

    Fairway, Kansas

    I'm interested

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

    I'm interested
Show all 12 locations
Who can participate

Inclusion criteria

  • ✓Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors with KRAS G12C mutation
  • ✓Received and progressed or been intolerant to prior standard therapy OR standard therapy is considered inappropriate OR an investigational agent is considered standard of care
  • ✓Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • ✓Adequate hematological, renal, and hepatic function
  • ✓Agrees not to participate in another interventional study while receiving study drug

Exclusion criteria

  • ✕Leptomeningeal disease or carcinomatous meningitis
  • ✕Clinically significant toxicity resulting from prior cancer therapies
  • ✕Known or suspected hypersensitivity to FMC-376 or any components of the study drug
  • ✕Condition that would interfere with study drug absorption
  • ✕Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.